Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab vs Verteporfin PDT in Neovascular AMD
NCT00390026Phase 3Withdrawn
- Sponsor
- St. Eriks Eye Hospital
- Start
- Nov 2006
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by St. Eriks Eye Hospital. Primary endpoint: Proportion of patients losing less than 15 letters on the ETDRS visual acuity chart at 1 year. Planned start Nov 2006; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00390026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390026.